Company

Drug

Indication

Trial Acronym

Phase

Abstract 

Abstract Title

PDC*line Pharma

PDC*lung01

NSCLC

NCT03970746

I/II

CT021

Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC

Elicio Therapeutics

ELI-002 2P

Pancreatic cancer

AMPLIFY-201 (NCT04853017)

I

CT022

Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study

Oncovir

Neoadjuvant Hiltonol (PolyICLC)

Prostate

Cancer

NCT03262103

I

CT023

Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot.

Scancell

SCIB1

Advanced unresectable melanoma

SCOPE

(NCT04079166)

II

CT024

A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial

BioSante

GVAX

Pancreatic adenocarcinoma

NCT03153410

Early Phase I

CT134

Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma

Genentech

Autogene cevumeran (RO7198457, RG6180)

Pancreatic ductal

adenocarcinoma (PDAC)

NCT05968326

II

CT025

Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

Syncromune

SV-102

Metastatic castrate-resistant prostate cancer (mCRPC)

NCT05544227

I

CT026

Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)